Ash A. Alizadeh
Stanford University
324 Papers
673 Citations
Ash A. Alizadeh is an academic researcher from Stanford University. The author has contributed to research in topics: Medicine & Biology. The author has an hindex of 69, co-authored 225 publications. Previous affiliations of Ash A. Alizadeh include National Institutes of Health & University of Miami.
Chat about Author
Papers
Noninvasive Detection of Ibrutinib Resistance in Non-Hodgkin Lymphoma Using Cell-Free DNA
Florian Scherer,David M. Kurtz,Aaron M. Newman,Alexander F.M. Craig,Henning Stehr,Li Zhou,Cynthia Glover,Holbrook E Kohrt,Ronald Levy,Maximilian Diehn,Ash A. Alizadeh +10 more
TL;DR: This study shows that noninvasive genotyping of blood plasma allows early detection of resistance mutations during Ibrutinib therapy in a patient with relapsed/refractory follicular lymphoma associated with histological transformation and detects the emergence of two independent BTK C481S resistance mutations in the blood plasma.
Specific post-translational histone modifications of neutrophil extracellular traps as immunogens and potential targets of lupus autoantibodies
Chih Long Liu,Stephanie Tangsombatvisit,Jacob M. Rosenberg,Gil Mandelbaum,Emily C Gillespie,Or Gozani,Ash A. Alizadeh,Paul J. Utz +7 more
TL;DR: Isolated in vivo exposure to NETs is insufficient to break tolerance and may involve additional factors that have yet to be identified.
End-of-Treatment Response Assessment after Frontline Therapy for Aggressive B-Cell Lymphoma: Landmark Comparison of a Singular PET/CT Scan Versus Ultrasensitive Circulating Tumor DNA
Mark Roschewski,Liza Lindenberg,Esther Mena,Rahul Lakhotia,Christopher Melani,Seth M. Steinberg,Andre Schultz,Gregory J. Hogan,Jacob J. Chabon,Sandra Close,Maximilian Diehn,Brian Sworder,David M. Kurtz,Ash A. Alizadeh,Wyndham H. Wilson +14 more
TL;DR: The prognostic utility of MRD was compared to standardized PET/CT scan at EOT to freedom-from-progression (FFP) and progression-free survival (PFS) and was reported as MRD positive when ctDNA levels exceeded an analytical detection threshold corresponding to 98% specificity.
Abstract 6560: Cell-free RNA analysis for non-invasive cancer detection and characterization
Monica Nesselbush,Bogdan A. Luca,Young-Jun Jeon,Isabel Jabara,Catherine Meador,Michael S. Binkley,Nova Xu,Angela B. Hui,Andrea Garofalo,William Y. Shi,Kevin J. Liu,Takeshi Sugio,Noah Kastelowitz,Emily G. Hamilton,Rene F. Bonilla,Yi Peng Wang,Alice Jiang,Brianna Lau,J. Eichholz,Mandeep Banwait,Joseph G Schroers-Martin,J. Boegeholz,Daniel A. King,Mohammad Shahrokh Esfahani,T. Raclin,Robert Tibshirani,Sandy Srinivas,Viswam S. Nair,J. Isbell,Bob T. Li,Zofia Piotrowska,Lecia V. Sequist,Aaron N Hata,Joel W. Neal,Heather A. Wakelee,Andrew J. Gentles,Ash A. Alizadeh,Maximilian Diehn +37 more
TL;DR: Rare-Seq is a novel ultrasensitive cfRNA sequencing method that enables non-invasive cancer detection and characterization. It has an estimated LOD95 of 0.05%, which is 52-fold better than whole transcriptome cfRNA profiling.